Sign up USA
Proactive Investors - Run By Investors For Investors

Soligenix shares skyrocket on RiVax development program news

Ricin is an extremely dangerous poison, which has been used as a weapon and by terrorists.
Soligenix shares skyrocket on RiVax development program news
Ricin has been used as a biological weapon

Soligenix Inc (NASDAQ:SNGX) shares surged over 52% in New York as it posted positive data on its ricin toxin vaccine called RiVax.

Ricin is an extremely dangerous poison, which has been used as a  weapon and by terrorists.

It  can be inhaled, injected, ingested, or absorbed through eyes or damaged skin.

A vaccine against it is hoped to deter its use as a biological weapon.

The firm has shown RiVax has enhanced thermostability and 100% protection in pre-clinical ricin aerosol challenge models and will be showcasing results from the candidate's development program at a conference in Bethesda, Maryland  from April 24  to 26.

It is hoped the findings will aid approval of RiVax by the US Food and Drug Administration (FDA).

Shares added 52.87% to $3.93.

View full SNGX profile View Profile

Soligenix Timeline

Related Articles

Cholesterol gauge
July 25 2017
The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use